AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 161 min read$AIM

Equels Thomas K purchased $5K of AIM

Equels Thomas K (CEO & President) purchased 22,000 shares of AIM ImmunoTech Inc. (AIM) at $0.22 on 2026-09-15.

Original reporting
SEC EDGAR · Equels Thomas K
Published Sep 16, 2026, 1:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 1:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AIM
Neutral
high confidence
Mentioned
$AIM
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AIMNeutralLow
01

Why it matters

The purchase is modest and unlikely to affect AIM's stock price materially.

02

Market read

Small insider buy; low trading relevance.

03

What to watch

Potential upcoming clinical data or financing events not disclosed in this filing.

Relevance 4/10Novelty 4/10Timing: transaction dated 2026-09-15, filed 2026-09-16

Background

Form 4 filings disclose insider trades; investors watch for material purchases.

Company-level read

Ticker impact

$AIMNeutralHigh confidence
Context

CEO Equels Thomas K bought 22,000 shares for $4,862, increasing his stake to 91,822 shares.

Expected impact

little to no immediate impact; may provide slight bullish bias.

Evidence & confidence

The transaction size ($5K) is negligible relative to market cap; insider buying is a positive signal but not material.

Market effects

Sector

None; isolated insider activity in biotech sector.

Regional

None; limited to AIM shareholders.

Global

None; no broader market effect.

Counterpoint

What could challenge this read

Insider purchase could be a routine portfolio adjustment, not a strong endorsement.

Key entities

  • Individual
    Equels Thomas K

    CEO & President of AIM ImmunoTech Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AIM insider trading history →

Related articles

AUG 10
$AIMLow

AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3…

AIM ImmunoTech Inc. (AIM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CONFIDENTIAL DRAFT NOT FOR IMMEDIATE RELEASE AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer Completed Enrollment and Ampligen Do

SEC EDGAR 8-K2 min
JUL 23
$AIMMedAI 8/10

AIM Stock Soars 42% As Pancreatic Cancer Trial Hits Key Enrollment Milestone Before Schedule — CEO Sees 'Significant Value-Inflection Period' Ahead

AIM ImmunoTech said its Phase 2 pancreatic cancer trial of Ampligen (rintatolimod) plus AstraZeneca’s Imfinzi (durvalumab) after FOLFIRINOX reached final patient enrollment ahead of schedule. The company expects to complete dosing and assess the primary Clinical Benefit Rate endpoint in December 2026, while continuing Phase 3 planning and expanding regulatory and IP efforts.

stocktwits.com4 min
JUL 9
$AIMMed

WA gold project Warrawoona fined $118,000 over threatened bat

Australia’s DCCEEW fined AIM Mining Corporation $118,000 for EPBC breaches at its Warrawoona Gold Project in WA’s Pilbara, tied to failure to protect the threatened Pilbara leaf-nosed bat. The regulator cited groundwater extraction over limits, missing species management steps, and reporting failures. AIM said it paid the fine. Calidus previously operated the project.

abc.net.au4 min